← Back to Search

JAK Inhibitor

CTP-543 for Alopecia Areata

Phase 2 & 3
Waitlist Available
Research Sponsored by Concert Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 276 weeks
Awards & highlights

Study Summary

This trial will look at the long-term safety of CTP-543 for hair loss in adults with alopecia areata.

Who is the study for?
This trial is for adults with moderate to severe alopecia areata who have already completed 24 weeks of treatment in a prior CTP-543 study. Participants should not have donated blood recently, must not have active scalp conditions needing topical treatments, and females should not be nursing, pregnant or planning pregnancy during the study and for a month after.Check my eligibility
What is being tested?
The trial is testing the long-term safety and effectiveness of a drug called CTP-543 for treating hair loss caused by alopecia areata. It's an extension study, meaning it continues from previous research on the same medication.See study design
What are the potential side effects?
While specific side effects of CTP-543 aren't listed here, common ones may include reactions at the pill intake site, gastrointestinal symptoms like nausea or diarrhea, headaches, fatigue or allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~276 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 276 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effect of CTP-543 on treating hair loss as measured by the Severity of Alopecia Tool (SALT)
Number of Participants with Adverse Events as a Measure of Safety

Side effects data

From 2022 Phase 3 trial • 706 Patients • NCT04518995
12%
Headache
9%
Acne
6%
Blood creatine phosphokinase (increased)
5%
COVID-19
5%
Nasopharyngitis
3%
Upper respiratory tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
CTP-543 8 mg BID
CTP-543 12 mg BID

Trial Design

1Treatment groups
Experimental Treatment
Group I: CTP-543Experimental Treatment1 Intervention
Patients who previously completed a qualifying CTP-543 clinical trial
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CTP-543
2021
Completed Phase 3
~2110

Find a Location

Who is running the clinical trial?

Concert PharmaceuticalsLead Sponsor
34 Previous Clinical Trials
3,411 Total Patients Enrolled
7 Trials studying Alopecia Areata
2,219 Patients Enrolled for Alopecia Areata

Media Library

CTP-543 (JAK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03898479 — Phase 2 & 3
Alopecia Areata Research Study Groups: CTP-543
Alopecia Areata Clinical Trial 2023: CTP-543 Highlights & Side Effects. Trial Name: NCT03898479 — Phase 2 & 3
CTP-543 (JAK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03898479 — Phase 2 & 3
Alopecia Areata Patient Testimony for trial: Trial Name: NCT03898479 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there specific requirements to qualify for this research project?

"This trial is for alopecia areata patients between 18 and 65. They are looking for 1000 participants in total."

Answered by AI

For this particular experiment, are elderly patients welcome?

"The age range for this clinical trial is 18 to 65. For patients that are under 18, there are 10 different studies and 67 for patients that are over 65."

Answered by AI

Are we still able to sign up new patients for this trial?

"Unfortunately, this study is no longer taking patients. It was originally posted on April 4th, 2019 but hasn't been updated since October 28th, 2022. However, there are currently 92 other trials that are recruiting patients."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
Florida
North Carolina
Other
How old are they?
65+
18 - 65
What site did they apply to?
Wake Forest University Health Sciences, Department of Dermatology
Austin Institute for Clinical Research, Inc.
Stanford University School of Medicine - Medical Dermatology Clinic
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
1
3+

Why did patients apply to this trial?

I have been only able to use holistic and over the counter. I've tried Finasteride and Minoxidil oral medication but did not work.
PatientReceived 2+ prior treatments
I have been suffering in silence with nothing that actually works, so this is my final step.
PatientReceived no prior treatments
I have suffered from hair loss since middle school. I would give anything to find something that works. It really affects your quality of life.
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
2019. "Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03898479.
All > Androgenetic Alopecia > Alopecia Areata
~16 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top